ArticleBlood2011
Efficacy of retreatment with immunomodulatory drugs (IMiDs) in patients receiving IMiDs for initial therapy of newly diagnosed multiple myeloma.
Article in Blood, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 60 citations in OpenAlex.
- Replacement of bortezomib with carfilzomib for multiple myeloma patients progressing from bortezomib combination therapy.Leukemia · 2014Trial
- Is There a Role for Daratumumab Retreatment in Patients with Relapsed/Refractory Multiple Myeloma?Biomedicines · 2025Review
- SUMOylation inhibition enhances multiple myeloma sensitivity to lenalidomide.Cancer gene therapy · 2023Article
- Lenalidomide in Multiple Myeloma: Review of Resistance Mechanisms, Current Treatment Strategies and Future Perspectives.Cancers · 2023Review
- Cancer therapies based on targeted protein degradation - lessons learned with lenalidomide.Nature reviews. Clinical oncology · 2021Review
- Pomalidomide Plus Low-Dose Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients: Results of the Real-World "POWERFUL" Study.Journal of clinical medicine · 2021Article
- Article
- Treatment of relapsed and refractory multiple myeloma.Blood research · 2020Review
- Efficacy of retreatment with immunomodulatory drugs and proteasome inhibitors following daratumumab monotherapy in relapsed and refractory multiple myeloma patients.British journal of haematology · 2018Observational
- Allogeneic stem cell transplantation and subsequent treatments as a comprehensive strategy for long-term survival of multiple myeloma patients.Bone marrow transplantation · 2017Article
- Sequencing of nontransplant treatments in multiple myeloma patients with active disease.Hematology. American Society of Hematology. Education Program · 2016Review
- Estimating the Economic Impact of Adding Panobinostat to a U.S. Formulary for Relapsed and/or Refractory Multiple Myeloma: A Budget Impact and Cost-Benefit Model.Journal of managed care & specialty pharmacy · 2016Article
- Treatment of relapsed and refractory multiple myeloma.Haematologica · 2016Review
- Evolving paradigms in the treatment of relapsed/refractory multiple myeloma: increased options and increased complexity.Bone marrow transplantation · 2016Review
- Current therapeutic strategies for multiple myeloma.International journal of clinical oncology · 2015Review
- Estimating the Costs of Therapy in Patients with Relapsed and/or Refractory Multiple Myeloma: A Model Framework.American health & drug benefits · 2015Article
- Evaluation of immunomodulatory drugs in multiple myeloma: single center experience.American journal of blood research · 2015Article
- Current treatment landscape for relapsed and/or refractory multiple myeloma.Nature reviews. Clinical oncology · 2015Review
- Thalidomide-analogue biology: immunological, molecular and epigenetic targets in cancer therapy.Oncogene · 2013Review
- Molecular mechanism of action of immune-modulatory drugs thalidomide, lenalidomide and pomalidomide in multiple myeloma.Leukemia & lymphoma · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 1 institution in 1 country.
Funding
Abstract
The efficacy of retreatment with immunomodulatory drugs (IMiDs) among patients with multiple myeloma who received this class of drugs for initial therapy is unknown. We studied 140 patients who received either thalidomide-dexamethasone (81; 58%) or lenalidomide-dexamethasone (59; 42%) as first-line therapy of multiple myeloma followed by repeat IMiD (thalidomide [34; 24%] or lenalidomide [106; 76%]) as one of the salvage regimens. A median of 2 treatments (range, 1-6), including a stem cell transplant in 105 patients (75%), were administered before IMiD-based salvage therapy. The median time from diagnosis to repeat exposure to IMiD was 28 months. Among the 113 evaluable patients, 50 (44%) achieved at least a partial response, and 63 (56%) achieved less than a partial response to repeat IMiD. Response rates with lenalidomide retreatment were higher than with repeat administration of thalidomide.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.